Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with hiv and hepatitis c virus

Clinical Infectious Diseases

Volumn 55, Issue 5, 2012, Pages 728-736

  Berenguer, Juan ^a   Rodríguez, Elena ^b   Miralles, Pilar ^a   Von Wichmann, Miguel A ^h   López Aldeguer, José ⁱ   Mallolas, Josep ^l   Galindo, María J ^j   Van Den Eynde, Eva ^m   Téllez, María J ^c   Quereda, Carmen ^d   Jou, Antoni ^o   Sanz, José ^p   Barros, Carlos ^q   Santos, Ignacio ^e   Pulido, Federico ^f   Guardiola, Josep M ⁿ   Ortega, Enrique ^k   Rubio, Rafael ^f   Jusdado, Juan J ^r   Montes, María L ^b,s   Gaspar, Gabriel ^t   Esteban, Herminia ^g   Bellón, José M ^a   González García, Juan ^b   more..

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g Fundacion SEIMC GESIDA   (Spain)

^h HOSPITAL DONOSTIA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO LA FE   (Spain)

^j Hospital Clinico Universitario   (Spain)

^k HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^l Hospital Clinic   (Spain)

^m HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

ⁿ HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^o HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^p HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

^q HOSPITAL DE MÓSTOLES   (Spain)

^r HOSPITAL SEVERO OCHOA   (Spain)

^s HOSPITAL UNIVERSITARIO DE GUADALAJARA   (Spain)

^t HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIVIRAL THERAPY; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEATH; DISEASE COURSE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RISK ASSESSMENT; SPAIN; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; COHORT STUDIES; COINFECTION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERONS; KAPLAN-MEIER ESTIMATE; MALE; PROPORTIONAL HAZARDS MODELS; RIBAVIRIN; SPAIN; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84864915019     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis500     Document Type: Article

References (33)

1. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-9.
2. Soriano V, Garcia-Samaniego J, Valencia E, Rodriguez-Rosado R, Munoz F, Gonzalez-Lahoz J. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIVinfected drug users. Eur J Epidemiol 1999; 15:1-4.
3. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to endstage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32:492-7.
4. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21:1073-89.
5. Camma C, Di Bona D, Schepis F, et al. Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data. Hepatology 2004; 39:333-42.
6. Coverdale SA, Khan MH, Byth K, et al. Effects of interferon treatment response on liver complications of chronic hepatitis C: 9-year followup study. Am J Gastroenterol 2004; 99:636-44.
7. Veldt BJ, Heathcote EJ, Wedemeyer H, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med 2007; 147:677-84.
8. Di Martino V, Crouzet J, Hillon P, Thevenot T, Minello A, Monnet E. Long-term outcome of chronic hepatitis C in a population-based cohort and impact of antiviral therapy: a propensity-adjusted analysis. J Viral Hepat 2011; 18:493-505.
9. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol 2011; 9:509-16. e1.
10. Lissen E, Clumeck N, Sola R, et al. Histological response to pegIFNalpha- 2a (40KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS 2006; 20:2175-81.
11. Berenguer J, Alvarez-Pellicer J, Martin PM, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50:407-13.
12. Greub G, Ledergerber B, Battegay M, et al. Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000; 356:1800-5.
13. The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20:15-20.
14. Wai CT, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-26.
15. Moreno S, Garcia-Samaniego J, Moreno A, et al. Noninvasive diagnosis of liver fibrosis in patients with HIV infection and HCV/HBV coinfection. J Viral Hepat 2009; 16:249-58.
16. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1-19.
17. Sulkowski MS, Moore RD, Mehta SH, Chaisson RE, Thomas DL. Hepatitis C and progression of HIV disease. JAMA 2002; 288: 199-206.
18. Peters L, Mocroft A, Soriano V, et al. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression. J Acquir Immune Defic Syndr 2009; 50:457-63.
19. d'Arminio Monforte A, Cozzi-Lepri A, Castagna A, et al. Risk of developing specific AIDS-defining illnesses in patients coinfected with HIV and hepatitis C virus with or without liver cirrhosis. Clin Infect Dis 2009; 49:612-22.
20. Potter M, Odueyungbo A, Yang H, Saeed S, Klein MB. Impact of hepatitis C viral replication on CD4+ T-lymphocyte progression in HIVHCV coinfection before and after antiretroviral therapy. AIDS 2010; 24:1857-65.
21. Kovacs A, Al-Harthi L, Christensen S, Mack W, Cohen M, Landay A. CD8+ T cell activation in women coinfected with human immunodeficiency virus type 1 and hepatitis C virus. J Infect Dis 2008; 197:1402-7.
22. Rempel H, Sun B, Monto A, Calosing C, Pulliam L. HCV Stimulates HIV immune activation in HIV/HCV co-infected Subjects on HAART (paper 672). In: 17th Conference on Retroviruses and Opportunistic Infections, San Francisco, California, 2010.
23. Kovacs A, Karim R, Mack WJ, et al. Activation of CD8 T cells predicts progression of HIV infection in women coinfected with hepatitis C virus. J Infect Dis 2010; 201:823-34.
24. de Oca Arjona MM, Marquez M, Soto MJ, et al. Bacterial translocation in HIV-infected patients with HCV cirrhosis: implication in hemodynamic alterations and mortality. J Acquir Immune Defic Syndr 2011; 56:420-7.
25. Mostafa A, Mohamed MK, Saeed M, et al. Hepatitis C infection and clearance: impact on atherosclerosis and cardiometabolic risk factors. Gut 2010; 59:1135-40.
26. Guiltinan AM, Kaidarova Z, Custer B, et al. Increased all-cause, liver, and cardiac mortality among hepatitis C virus-seropositive blood donors. Am J Epidemiol 2008; 167:743-50.
27. Weber R, Sabin C, Reiss P, et al. HBV or HCV coinfections and risk of myocardial infarction in HIV-infected individuals: the D:A:D Cohort Study. Antivir Ther 2010; 15:1077-86.
28. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011; 62:141-55.
29. de Castro IF, Micheloud D, Berenguer J, et al. Hepatitis C virus infection is associated with endothelial dysfunction in HIV/hepatitis C virus coinfected patients. AIDS 2010; 24:2059-67.
30. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001; 104:1336-42.
31. Macias J, Berenguer J, Japon MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009; 50:1056-63.
32. Propst-Graham KL, Preheim LC, Vander Top EA, Snitily MU, Gentry- Nielsen MJ. Cirrhosis-induced defects in innate pulmonary defenses against Streptococcus pneumoniae. BMC Microbiol 2007; 7:94.
33. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54:1433-44.